We are now at the start of the largest meeting in the world for Pharma and Biotech and the data released at this conference can have significant implications for biotech investors. The conference is the 2012 meeting of the American Society of Clinical Oncology (ASCO) being held from June 1 to June 5 in Chicago IL. Presenters will range from Genentech, Eli Lilly & Co. (LLY), Bristol-Myers Squibb Co (BMY), Dendreon Corporation (DNDN), to the innovative entities fronting the cancer stem cell and cancer vaccine space among many others.
Such information released by these companies is important not only for investors but also to patients seeking access to these critical and novel treatments (something which investors contribute greatly to). Although not all will be presenting ground breaking new clinical data, many will and I will be looking to obtain that data, summarize it from its occasionally complicated form and present it here. I will so be looking to interview a few of the leaders in this race such as CEO's as well as CSO's or key clinical/scientific leads. My intention is to educate people in the hope to give them access to better decisions in their investment choices.
Currently there are 2,744 abstracts that will be physically presented at this conference in varying subjects with the majority of them covering subjects such as Genitourinary Cancer, Breast Cancer, Central Nervous system Cancer, Gastrointestinal (Colorectal) Cancer, Leukemia, Myelodysplasia, Lymphoma and Lung among others with the least covering subjects like Pediatric oncology.
My concentration will mainly focus on innovative data along with what I feel are next generation fields (areas) in the oncology space and these include cancer stem cells, immune modulators and cancer vaccines. These are still very new and will likely carve out a significant portion of the oncology drug development product space in the next decade.
Some of the specifics I will be looking into are BMS anti-PD-1 antibody which has shown beneficial survival effects in patients with melanoma brain tumors, Threshold Pharmaceuticals, Inc. (THLD) and its Phase III Hypoxia-Targeted Drug TH-302, Exelixis (EXEL) with its MET and VEGF receptor inhibitors, Cell Therapeutics (CTIC) and its lead candidate pixantrone (Pixuvri), ImmunoCellular Therapeutics (IMUC) with ICT-107 for Glioblastoma multiforme (GBM), Galena Biopharma (GALE) and cancer vaccine NeuVax™ as well as Rindopepimut® (CDX-110) by Celldex Therapeutics, Inc. (CLDX) among others.
Please look here and at my website for daily updates.
Disclosure: I am long IMUC.